The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study

Keyphrases

• Clinically Significant 14%
• Denmark 14%
• Double Dummy 14%
• Efficacy Analysis 14%
• Exclusion Criteria 14%
• Finland 14%
• Intent-to-treat 14%
• Moderate to Severe 42%
• Mometasone Furoate Nasal Spray 100%
• Nasal Congestion 28%
• Nasal Congestion Score 14%
• Nasal Polyposis 100%
• Nasal Polyps 14%
• Norway 14%
• Once-daily 100%
• Peak Nasal Inspiratory Flow 14%
• Placebo 14%
• Placebo Groups 14%
• Placebo-controlled Clinical Trial 14%
• Polyp Size 28%
• Quality of Life 14%
• Quality of Life Measures 14%
• Randomized Double-blind 14%
• Randomized Double-blind Placebo-controlled Study 100%
• Sense of Smell 14%
• Significant Benefit 14%
• Sweden 14%
• Unexpected Adverse Event 14%
• Well Tolerated 14%

Medicine and Dentistry

• Adverse Event 14%
• Controlled Clinical Trial 14%
• Intention-to-Treat Analysis 14%
• Mometasone Furoate 100%
• Nasal Congestion 42%
• Nasal Polyp 100%
• Nasal Spray 100%
• Peak Nasal Inspiratory Flow 14%
• Placebo 42%
• Placebo-Controlled Study 100%
• Polyp 28%
• Quality of Life 14%
• Quality of Life Measure 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 14%
• Controlled Clinical Trial 14%
• Mometasone Furoate 100%
• Nasal Spray 100%
• Nose Obstruction 42%
• Nose Polyp 100%
• Placebo 42%
• Placebo-Controlled Study 100%
• Polyp 28%